China’s bio medicine company Zhimeng Biopharma raised nearly a hundred million yuan in a series Pre-A round funding led by Zeyue Capital and Shenzhen Capital Group. The investment will be used on application on clinical research and development of subsequent pipeline.
Established in 2015, Zhimeng Biopharma is committed to treating Chronic Hepatitis B and hepatic diseases, and the development of innovative medicine for central nervous system diseases.
South Africa Today
Read more at VolaNews
Disclaimer: The views of authors published on South Africa Today are their own and do not necessarily represent the views of South Africa Today. By viewing, visiting, using, or interacting with SouthAfricaToday.net, you are agreeing to all the provisions of the Terms of Use Policy and the Privacy Policy.
